Dybbs Michael 4
4 · Kalaris Therapeutics, Inc. · Filed Jun 4, 2026
Research Summary
AI-generated summary of this filing
Kalaris (KLRS) Director Michael Dybbs Receives 9,000-Share Award
What Happened
Michael Dybbs, a director of Kalaris Therapeutics, received a derivative award on June 3, 2026 covering 9,000 shares. The grant is reported as a zero-dollar acquisition (no cash paid at grant) and represents an equity award (option/award) rather than an open-market purchase or sale. This is a compensation/award transaction — not an immediate purchase or sale.
Key Details
- Transaction date: 2026-06-03; Form 4 filed 2026-06-04 (timely filing).
- Transaction type/code: A (Grant, award or other acquisition); 9,000 shares @ $0.00 (derivative).
- Vesting: The underlying shares are scheduled to vest in full on the earlier of (i) June 3, 2027 or (ii) the issuer’s 2027 Annual Meeting of Stockholders, subject to continued service (footnote F1).
- Shares owned after transaction: not specified in the excerpt provided.
- No sale or exercise occurred — this is an award grant, not a cashless exercise or market transaction.
Context
This is a routine director equity grant (compensation) that vests based on continued service and a time/meeting-based milestone. Derivative grants like this do not reflect an immediate market purchase or sale and do not provide immediate liquidity; they align director compensation with future company performance or continued service.
Insider Transaction Report
- Award
Stock Option (Right to Buy)
[F1]2026-06-03+9,000→ 9,000 totalExercise: $4.72Exp: 2036-06-02→ Common Stock (9,000 underlying)
Footnotes (1)
- [F1]The option was granted on June 3, 2026. The shares underlying the option are scheduled to vest in full on the earlier of (i) June 3, 2027 or (ii) the date of the Issuer's 2027 Annual Meeting of Stockholders, subject to continued service.